Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

ORR was significantly lower, however, and PFS showed a trend toward a shorter duration in peritoneal dissemination, suggesting that patients with peritoneal dissemination in DGC may not achieve comparable treatment efficacy to those without peritoneal dissemination, even in the first-line setting.

also in 53,322 other papers